Eli Lilly Earnings Have Wall Street Asking New Questions About GLP-1 Drugs. Is Something Going Wrong?
One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...
STAT6d
Lilly’s earnings surprise, investors mull the election, & a spooky ghost story
On the Readout LOUD podcast, hear what a Harris or Trump presidency would mean for health care policy, and learn about Eli ...
Her6d
On the hunt for your next career opportunity? Lilly Limerick is now hiring and this could be your chance to join a groundbreaking team
Brought to you by Eli LillyFeeling stagnant at work? Hungry for change? Craving something new? Your new career could ...
Eli Lilly’s Resilient Outlook: Buy Rating Affirmed Despite Q3 Challenges
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
Irish Examiner7d
Lilly: Driving innovation, sustainability, and equality in Limerick and beyond
Lilly Limerick is set to be the global pharmaceutical leader's most technically advanced manufacturing site to date ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
clickondetroit.com7d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...
Eli Lilly had a strong Q3, so why is its stock falling?
Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to ...